LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone
Phase 1/2Active 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia
Trial Timeline
Nov 9, 2020 → Nov 30, 2029
NCT ID
NCT04408625About LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone is a phase 1/2 stage product being developed by Eli Lilly for Frontotemporal Dementia. The current trial status is active. This product is registered under clinical trial identifier NCT04408625. Target conditions include Frontotemporal Dementia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04408625 | Phase 1/2 | Active |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| galantamine hydrobromide | Johnson & Johnson | Phase 2 | 52 |
| memantine hydrochloride | Lundbeck | Phase 3 | 74 |
| Syntocinon | Brain Biotech | Phase 2 | 44 |
| DNL593 + Placebo | Denali Therapeutics | Phase 1/2 | 36 |
| PBFT02 | Passage Bio | Phase 1/2 | 33 |